Claims
- 1. A method of evaluating an adenoviral vector composition, wherein the composition comprises (a) at least 1×104 particles of an adenoviral vector comprising an adenoviral genome, wherein the adenoviral vector is an human subgroup C adenoviral vector deficient in at least the E1 region of the adenoviral genome and the E4 region of the adenoviral genome, and (b) a carrier therefor, wherein the method comprises (i) evaluating the ratio of the number of particles of the adenoviral vector to the number of particles of E1-revertant replication-deficient adenoviral vectors not deficient in the E1 region of the adenoviral genome, wherein the ratio of the number of particles of the adenoviral vector to the number of particles of E1-revertant replication-deficient adenoviral vectors not deficient in the E1 region of the adenoviral genome is greater than 1×106:1, and (ii) evaluating the ratio of the number of particles of the adenoviral vector to the number of particles of replication-competent adenoviral vectors, wherein the ratio of the number of particles of the adenoviral vector to the number of particles of the replication-competent adenoviral vector is greater than 1×107:1.
- 2. The method of claim 1, wherein the composition comprises at least 1×1010 particles of the adenoviral vector.
- 3. The method of claim 2, wherein the ratio of the number of particles of the adenoviral vector to the number of particles of E1-revertant replication-deficient adenoviral vectors not deficient in the E1 region of the adenoviral genome is greater than 1×107:1.
- 4. The method of claim 3, wherein the ratio of the number of particles of the adenoviral vector to the number of particles of E1-revertant replication-deficient adenoviral vectors not deficient in the E1 region of the adenoviral genome is greater than 1×108:1.
- 5. The method of claim 4, wherein the ratio of the number of particles of the adenoviral vector to the number of particles of E1-revertant replication-deficient adenoviral vectors not deficient in the E1 region of the adenoviral genome is greater than 1×109:1.
- 6. The method of claim 5, wherein the ratio of the number of particles of the adenoviral vector to the number of particles of E1-revertant replication-deficient adenoviral vectors not deficient in the E1 region of the adenoviral genome is greater than 1×111010:1.
- 7. The method of claim 1, wherein the adenoviral vector is deficient in the E2 region of the adenoviral genome.
- 8. The method of claim 1, wherein the adenoviral vector is deficient in a late region of the adenoviral genome.
- 9. The method of claim 1, wherein the adenoviral vector is deficient in all regions required for viral replication.
- 10. The method of claim 9, wherein the adenoviral vector comprises at least one adenoviral inverted terminal repeat and one or more adenoviral promoters.
- 11. The method of claim 9, wherein the adenoviral vector comprises at least one adenoviral inverted terminal repeat and a packaging signal.
- 12. The method of claim 1, wherein the composition comprises 1×101 to 1×1013 particles of the adenoviral vector.
- 13. The method of claim 1, wherein the composition comprises about 10 ng/ml or less of E1 protein.
- 14. The method of claim 1, wherein the adenoviral vector comprises a heterologous nucleic acid sequence.
- 15. The method of claim 14, wherein the heterologous nucleic acid sequence is located in the E1 region.
- 16. The method of claim 14, wherein the heterologous nucleic acid sequence encodes tumor necrosis factor-α, a vascular endothelial growth factor, a pigment-epithelial derived factor, or an atonal-associated factor.
- 17. The method of claim 16, wherein the heterologous nucleic acid sequence encodes tumor necrosis factor-α.
- 18. The method of claim 14, wherein the heterologous nucleic acid sequence is located in the E1 region and/or the E4 region.
- 19. The method of claim 18, wherein the heterologous nucleic acid sequence encodes tumor necrosis factor-α, a vascular endothelial growth factor, a pigment-epithelial derived factor, or an atonal-associated factor.
- 20. The method of claim 1, wherein the adenoviral vector comprises a spacer sequence in the E4 region.
- 21. The method of claim 1, wherein the adenoviral vector comprises a packaging domain located downstream of the E1 region.
- 22. The method of claim 21, wherein the packaging domain is located downstream of the E4 region.
- 23. The method of claim 1, wherein the adenoviral vector is serotype 2.
- 24. The method of claim 1, wherein the adenoviral vector is serotype 5.
- 25. The method of claim 1, wherein step (i) comprises:
(i-a) providing one or more cells that complement in trans for the deficiencies in the adenoviral genome of the adenoviral vector, except for the deficiencies of the E1 adenoviral region, (i-b) contacting one or more of the cells with a sample of the composition, (i-c) culturing the cells in a medium, and (i-d) determining whether an E1-revertant adenoviral vector is present in the composition by analyzing the propagation of any adenoviral vector.
- 26. The method of claim 25, wherein the adenoviral vector is serotype 2.
- 27. The method of claim 25, wherein the adenoviral vector is serotype 5.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This patent application is a continuation of copending U.S. patent application Ser. No. 10/001,097, filed Nov. 2, 2001.
Continuations (1)
|
Number |
Date |
Country |
Parent |
10001097 |
Nov 2001 |
US |
Child |
10844133 |
May 2004 |
US |